drugset / Trial / NCT00299390

Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer

NCT00299390

Phase 2 Terminated 10 enrolled Bayer
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether the study drug is effective and safe in the first line treatment of patients with small cell lung cancer

Timeline

Start
2006-04
Primary completion
2007-04
Completion
2007-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Sagopilone Small molecule 16 mg/m2 Intravenous